Regeneron Eylea Feels the Pinch as Kodiak Advances Extended Dosing for Eye Drug

기사 요약

Regeneron stock drops as Kodiak Sciences reports Phase 3 wAMD data showing Zenkuda rivals Eylea with extended six-month dosing schedules.